TITO R MENDOZA to Patient Reported Outcome Measures
This is a "connection" page, showing publications TITO R MENDOZA has written about Patient Reported Outcome Measures.
Connection Strength
3.299
-
New Developments in the Use of Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. Adv Exp Med Biol. 2020; 1244:335-339.
Score: 0.484
-
Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies. Adv Exp Med Biol. 2018; 995:165-182.
Score: 0.422
-
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clin Trials. 2017 Jun; 14(3):255-263.
Score: 0.399
-
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach. Qual Life Res. 2024 Apr; 33(4):1075-1084.
Score: 0.161
-
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
Score: 0.145
-
Effects of patient-reported outcome assessment order. Clin Trials. 2022 06; 19(3):307-315.
Score: 0.140
-
Development and Validation of a Patient-reported Outcome Measure for Gastrointestinal Obstruction in the Setting of Advanced Malignancy. Ann Surg. 2022 Dec 01; 276(6):e805-e811.
Score: 0.130
-
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021 02; 18(1):104-114.
Score: 0.129
-
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 2020 02; 21(2):e97-e103.
Score: 0.122
-
Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174.
Score: 0.120
-
Patient-reported outcomes in light of supportive medications in treatment-na?ve lung cancer patients. Support Care Cancer. 2020 Apr; 28(4):1809-1816.
Score: 0.117
-
Interpreting Patient-reported Outcome Scores for Clinical Research and Practice: Definition, Determination, and Application of Cutpoints. Med Care. 2019 05; 57 Suppl 5 Suppl 1:S8-S12.
Score: 0.116
-
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res. 2018 Dec; 27(12):3229-3241.
Score: 0.111
-
Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer. 2019 Mar; 27(3):1021-1028.
Score: 0.110
-
Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncol. 2018 03; 19(3):e173-e180.
Score: 0.107
-
What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE? Response Scales. J Pain Symptom Manage. 2018 03; 55(3):e3-e6.
Score: 0.104
-
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):409-418.
Score: 0.099
-
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1107-14.
Score: 0.093
-
Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer. 2016 07; 24(7):2843-51.
Score: 0.092
-
Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol. 2023 05; 201(4):738-746.
Score: 0.038
-
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther. 2021 11; 27(11):930.e1-930.e10.
Score: 0.034
-
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
Score: 0.026